O-4MD Tablets

Ondansetron Orally Disintegrating Tablet IP 4mg

• FDA approved antiemetic, a highly selective serotonin 5-HT3 receptor antagonist
• Causes no sedation, extrapyramidal reactions
• Success rate of Ondansetron (97%) and metoclopramide (45%) in controlling RIE on the day of radio therapy 1919 Sp (336-48

Use in: 

• Nausea & vomiting associated with cytotoxic radiotherapy & chemotherapy
• Postoperative nausea & vomiting
• Nausea & vomiting due to acute or chronic medical illness or acute gastroenteritis